Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York. Show more

1185 Avenue of the Americas, New York, NY, 10036, United States

Biotechnology

Healthcare

Market Cap

177.2M

52 Wk Range

$1.98 - $5.01

Previous Close

$4.38

Open

$4.40

Volume

155,576

Day Range

$3.98 - $4.40

Enterprise Value

112.1M

Cash

65.84M

Avg Qtr Burn

-2.915M

Insider Ownership

17.84%

Institutional Own.

37.08%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ORMD-0801 (ORA-D-013-1) Details Diabetes, Type 2 diabetes	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORMD-0801 Details Non-alcoholic steatohepatitis , Liver disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.